Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05470140 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Wugen.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05470140 is a Phase 1 study that has completed, run by Wugen. The registered enrollment target is 9 participants.
The verdict
NCT05470140, a Phase 1 study, has completed, sponsored by Wugen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML.
Interventions
- BIOLOGICAL WU-NK-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05470140
The ClinicalTrials.gov registry entry for NCT05470140 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wugen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WU-NK-101 is the first listed.
NCT05470140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05470140 about?
NCT05470140 is a clinical study titled "A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)". This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML.
What is the current status of trial NCT05470140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-07-01. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT05470140?
The interventions under investigation include: WU-NK-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05470140?
This trial is sponsored by Wugen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.